antibodi
human
coronaviru
human
sera
measur
haemagglutin
inhibit
hi
complement
fixat
cf
radial
diffusionhaemolysi
gel
hig
techniqu
appar
hi
titr
fraction
sera
antibodi
detect
two
method
found
reduc
consider
treat
sera
phospholipas
c
plc
plc
treatment
also
reduc
appar
hi
titr
sera
contain
variabl
amount
cf
andor
hig
antibodi
affect
antibodi
determin
two
latter
method
result
suggest
fals
posit
result
obtain
hi
test
unless
sera
treat
phospholipas
c
assay
previou
studi
found
rel
larg
fraction
human
sera
haemagglutinationinhibit
hi
activ
mousebrain
grown
human
coronaviru
fail
induc
haemolysi
newli
develop
radial
diffusionhaemolysi
gel
hig
assay
antibodi
method
wide
use
remov
nonspecif
inhibitor
viral
haemagglutin
treatment
sera
kaolin
period
heparinmanganes
aceton
receptordestroy
enzym
remov
hi
activ
sera
two
sera
subject
sediment
veloc
analysi
linear
sucros
gradient
show
singl
major
peak
hi
activ
find
taken
togeth
fact
report
literatur
nonspecif
serum
inhibitor
haemagglutin
prompt
us
suggest
sera
contain
subclass
hi
antibodi
measur
hig
test
hiposit
higncg
sera
reexamin
found
contain
nonspecif
serum
inhibitor
oc
haemagglutin
could
remov
pretreat
sera
phospholipas
c
sera
pair
patient
sera
origin
select
coronavirusantibodi
assay
basi
aetiolog
suspect
viral
diseas
reveal
routin
antiviralantibodi
screen
carri
diagnost
laboratori
depart
aliquot
sera
kept
frozen
year
reexamin
present
studi
togeth
sera
select
randomli
recent
routin
dignost
laboratori
materi
remov
ofnonspecif
lnbibitor
phospholipas
c
treatment
carri
essenti
describ
hauken
blom
rubella
antibodi
assay
treatment
kaolin
heparinmanganes
period
receptordestroy
enzym
accord
standard
techniqu
redcel
absorpt
aliquot
prewash
rat
erythrocyt
suspend
nine
volum
dilut
test
serum
incub
rain
room
temperatur
antigen
prepar
viru
strain
origin
obtain
dr
estola
state
veterinari
institut
helsinki
propag
suckl
mous
brain
describ
neurolog
symptom
appear
mice
kill
overdos
ether
brain
collect
minc
vv
suspens
made
melnick
medium
suspens
centrifug
min
g
supernat
suspens
use
antigen
assay
antigen
titr
rang
ha
test
use
rat
erythrocyt
complement
fixat
cf
serolog
test
haemagglutin
inhibit
assay
serum
antigen
dilut
made
dulbecco
phosphat
buffer
salin
dival
cation
ph
contain
bovin
serum
albumin
hi
test
ha
unit
antigen
incub
serum
dilut
min
room
temperatur
one
volum
rat
erythrocyt
buffer
ad
anoth
hour
rat
erythrocyt
use
instead
chicken
red
blood
cell
markedli
higher
antigen
titr
record
former
cell
sera
pretreat
mean
assay
unless
otherwis
indic
sera
heat
rain
standard
microwel
complement
fixat
test
prior
hig
assay
hig
gel
plate
kindli
prepar
mr
p
heinonen
mr
terttu
viininen
orion
diagnostica
helsinki
veloc
sediment
analysi
sera
carri
essenti
describ
vesikari
vaheri
phospholipas
c
enzym
use
success
remov
lipid
inhibitor
rubella
viru
haemagglutin
human
sera
anoth
indic
use
studi
came
work
r
bingham
cowork
shown
treat
avian
infecti
bronchiti
viru
enzym
one
induc
haemagglutin
activ
purifi
viru
prepar
previous
lack
activ
hiposit
sera
report
previou
studi
still
avail
subject
reexamin
hig
standard
hitest
also
assay
complementfix
method
previou
find
appar
discrep
hig
result
hi
titr
confirm
similar
disagr
hi
hig
test
also
observ
group
recent
collect
sera
heatinactiv
erythrocyteabsorpt
sera
alter
hi
titr
significantli
contrast
treat
sera
h
wv
phospholipas
c
follow
inactiv
enzym
wv
found
reduc
hi
titr
sera
factor
decreas
titr
markedli
sera
howev
hiactiv
higneg
sera
affect
treatment
expect
hititr
also
significantli
reduc
enzym
treatment
sera
also
complementfix
antibodi
viru
titr
obtain
cf
hig
test
reduc
treatment
exampl
differ
type
reaction
toward
phospholipas
c
treatment
given
tabl
number
sera
test
far
still
small
allow
calcul
frequenc
nonspecif
inhibitor
clear
rare
low
concentr
also
includ
nonspecif
inhibitor
remain
character
detail
studi
four
sera
far
analyz
veloc
sediment
analysi
sucro
e
gradient
major
part
phospholipas
c
sensit
hi
activ
sediment
top
gradient
conclus
shown
human
sera
contain
phospholipas
c
sensit
nonspecif
inhibitor
coronaviru
haemagglutin
surpris
find
differ
nonimmunoglobulin
serum
compon
known
interfer
haemagglutin
induc
virus
treatment
phospholipas
c
recommend
human
sera
assay
antibodi
viru
hi
test
